3beq › Citations

Structural characterization of the 1918 influenza virus H1N1 neuraminidase.

Xu X, Zhu X, Dwek RA, Stevens J, Wilson IA
J Virol 82 10493-501 (2008)
Cited: 180 times
EuropePMC logo PMID: 18715929

Abstract

Influenza virus neuraminidase (NA) plays a crucial role in facilitating the spread of newly synthesized virus in the host and is an important target for controlling disease progression. The NA crystal structure from the 1918 "Spanish flu" (A/Brevig Mission/1/18 H1N1) and that of its complex with zanamivir (Relenza) at 1.65-A and 1.45-A resolutions, respectively, corroborated the successful expression of correctly folded NA tetramers in a baculovirus expression system. An additional cavity adjacent to the substrate-binding site is observed in N1, compared to N2 and N9 NAs, including H5N1. This cavity arises from an open conformation of the 150 loop (Gly147 to Asp151) and appears to be conserved among group 1 NAs (N1, N4, N5, and N8). It closes upon zanamivir binding. Three calcium sites were identified, including a novel site that may be conserved in N1 and N4. Thus, these high-resolution structures, combined with our recombinant expression system, provide new opportunities to augment the limited arsenal of therapeutics against influenza.

Articles - 3beq mentioned but not cited (30)

  1. New world bats harbor diverse influenza A viruses. Tong S, Zhu X, Li Y, Shi M, Zhang J, Bourgeois M, Yang H, Chen X, Recuenco S, Gomez J, Chen LM, Johnson A, Tao Y, Dreyfus C, Yu W, McBride R, Carney PJ, Gilbert AT, Chang J, Guo Z, Davis CT, Paulson JC, Stevens J, Rupprecht CE, Holmes EC, Wilson IA, Donis RO. PLoS Pathog 9 e1003657 (2013)
  2. Structural characterization of the 1918 influenza virus H1N1 neuraminidase. Xu X, Zhu X, Dwek RA, Stevens J, Wilson IA. J Virol 82 10493-10501 (2008)
  3. Conserved and host-specific features of influenza virion architecture. Hutchinson EC, Charles PD, Hester SS, Thomas B, Trudgian D, Martínez-Alonso M, Fodor E. Nat Commun 5 4816 (2014)
  4. Prevalence of epistasis in the evolution of influenza A surface proteins. Kryazhimskiy S, Dushoff J, Bazykin GA, Plotkin JB. PLoS Genet 7 e1001301 (2011)
  5. Mapping the phosphoproteome of influenza A and B viruses by mass spectrometry. Hutchinson EC, Denham EM, Thomas B, Trudgian DC, Hester SS, Ridlova G, York A, Turrell L, Fodor E. PLoS Pathog 8 e1002993 (2012)
  6. Crystal structures of two subtype N10 neuraminidase-like proteins from bat influenza A viruses reveal a diverged putative active site. Zhu X, Yang H, Guo Z, Yu W, Carney PJ, Li Y, Chen LM, Paulson JC, Donis RO, Tong S, Stevens J, Wilson IA. Proc Natl Acad Sci U S A 109 18903-18908 (2012)
  7. Mapping the sequence mutations of the 2009 H1N1 influenza A virus neuraminidase relative to drug and antibody binding sites. Maurer-Stroh S, Ma J, Lee RT, Sirota FL, Eisenhaber F. Biol Direct 4 18; discussion 18 (2009)
  8. A computational-experimental approach identifies mutations that enhance surface expression of an oseltamivir-resistant influenza neuraminidase. Bloom JD, Nayak JS, Baltimore D. PLoS One 6 e22201 (2011)
  9. Genetic diversity of the 2009 pandemic influenza A(H1N1) viruses in Finland. Ikonen N, Haanpää M, Rönkkö E, Lyytikäinen O, Kuusi M, Ruutu P, Kallio-Kokko H, Mannonen L, Lappalainen M, Ziegler T, Julkunen I. PLoS One 5 e13329 (2010)
  10. Assembly of subtype 1 influenza neuraminidase is driven by both the transmembrane and head domains. da Silva DV, Nordholm J, Madjo U, Pfeiffer A, Daniels R. J Biol Chem 288 644-653 (2013)
  11. Computational screen and experimental validation of anti-influenza effects of quercetin and chlorogenic acid from traditional Chinese medicine. Liu Z, Zhao J, Li W, Shen L, Huang S, Tang J, Duan J, Fang F, Huang Y, Chang H, Chen Z, Zhang R. Sci Rep 6 19095 (2016)
  12. Structure-Based Modification of an Anti-neuraminidase Human Antibody Restores Protection Efficacy against the Drifted Influenza Virus. Jiang H, Peng W, Qi J, Chai Y, Song H, Bi Y, Rijal P, Wang H, Oladejo BO, Liu J, Shi Y, Gao GF, Townsend AR, Wu Y. mBio 11 e02315-20 (2020)
  13. Structure of influenza virus N7: the last piece of the neuraminidase "jigsaw" puzzle. Sun X, Li Q, Wu Y, Wang M, Liu Y, Qi J, Vavricka CJ, Gao GF. J Virol 88 9197-9207 (2014)
  14. Polar residues and their positional context dictate the transmembrane domain interactions of influenza A neuraminidases. Nordholm J, da Silva DV, Damjanovic J, Dou D, Daniels R. J Biol Chem 288 10652-10660 (2013)
  15. Interface dynamics explain assembly dependency of influenza neuraminidase catalytic activity. von Grafenstein S, Wallnoefer HG, Kirchmair J, Fuchs JE, Huber RG, Schmidtke M, Sauerbrei A, Rollinger JM, Liedl KR. J Biomol Struct Dyn 33 104-120 (2015)
  16. Structure determination of the 1918 H1N1 neuraminidase from a crystal with lattice-translocation defects. Zhu X, Xu X, Wilson IA. Acta Crystallogr D Biol Crystallogr D64 843-850 (2008)
  17. Experimental validation and computational modeling of anti-influenza effects of quercetin-3-O-α-L-rhamnopyranoside from indigenous south African medicinal plant Rapanea melanophloeos. Mehrbod P, Ebrahimi SN, Fotouhi F, Eskandari F, Eloff JN, McGaw LJ, Fasina FO. BMC Complement Altern Med 19 346 (2019)
  18. In-Silico screening of Pleconaril and its novel substituted derivatives with Neuraminidase of H1N1 Influenza strain. Hussain Basha S, Prasad RN. BMC Res Notes 5 105 (2012)
  19. Inhibition activity of a traditional Chinese herbal formula Huang-Lian-Jie-Du-Tang and its major components found in its plasma profile on neuraminidase-1. Zhou X, Li H, Shi Z, Gao S, Wei S, Li K, Wang J, Li J, Wang R, Gong M, Zhao Y, Xiao X. Sci Rep 7 15549 (2017)
  20. Identification of neuraminidase inhibitors against dual H274Y/I222R mutant strains. Hsu KC, Hung HC, HuangFu WC, Sung TY, Eight Lin T, Fang MY, Chen IJ, Pathak N, Hsu JT, Yang JM. Sci Rep 7 12336 (2017)
  21. A novel pathogenic mechanism of highly pathogenic avian influenza H5N1 viruses involves hemagglutinin mediated resistance to serum innate inhibitors. Panaampon J, Ngaosuwankul N, Suptawiwat O, Noisumdaeng P, Sangsiriwut K, Siridechadilok B, Lerdsamran H, Auewarakul P, Pooruk P, Puthavathana P. PLoS One 7 e36318 (2012)
  22. Amino acid determinants conferring stable sialidase activity at low pH for H5N1 influenza A virus neuraminidase. Takahashi T, Nidom CA, Quynh Le MT, Suzuki T, Kawaoka Y. FEBS Open Bio 2 261-266 (2012)
  23. Educational Material about Influenza Viruses. Lakdawala SS, Nair N, Hutchinson E. Viruses 11 E231 (2019)
  24. Molecular-level simulation of pandemic influenza glycoproteins. Amaro RE, Li WW. Methods Mol Biol 819 575-594 (2012)
  25. Molecular modeling studies demonstrate key mutations that could affect the ligand recognition by influenza AH1N1 neuraminidase. Ramírez-Salinas GL, García-Machorro J, Quiliano M, Zimic M, Briz V, Rojas-Hernández S, Correa-Basurto J. J Mol Model 21 292 (2015)
  26. In Silico Analysis to Compare the Effectiveness of Assorted Drugs Prescribed for Swine flu in Diverse Medicine Systems. Raja K, Prabahar A, Selvakumar S, Raja TK. Indian J Pharm Sci 76 10-18 (2014)
  27. Molecular modeling and lead design of substituted zanamivir derivatives as potent anti-influenza drugs. Dholakia D, Goyal S, Jamal S, Singh A, Das A, Grover A. BMC Bioinformatics 17 512 (2016)
  28. A novel N-heterocycles substituted oseltamivir derivatives as potent inhibitors of influenza virus neuraminidase: discovery, synthesis and biological evaluation. Zhang J, Liu C, Jia R, Zhang X, Zhang J, Bertagnin C, Bonomini A, Guizzo L, Jiang Y, Jia H, Jia S, Ma X, Loregian A, Huang B, Zhan P, Liu X. J Enzyme Inhib Med Chem 38 2277135 (2023)
  29. Discovery of Novel Boron-Containing N-Substituted Oseltamivir Derivatives as Anti-Influenza A Virus Agents for Overcoming N1-H274Y Oseltamivir-Resistant. Jia R, Zhang J, Zhang J, Bertagnin C, Bonomini A, Guizzo L, Gao Z, Ji X, Li Z, Liu C, Ju H, Ma X, Loregian A, Huang B, Zhan P, Liu X. Molecules 27 6426 (2022)
  30. Optimisation of Neuraminidase Expression for Use in Drug Discovery by Using HEK293-6E Cells. Campbell AC, Tanner JJ, Krause KL. Viruses 13 1893 (2021)


Reviews citing this publication (19)

  1. Advances in the development of influenza virus vaccines. Krammer F, Palese P. Nat Rev Drug Discov 14 167-182 (2015)
  2. Influenza neuraminidase. Air GM. Influenza Other Respir Viruses 6 245-256 (2012)
  3. Influenza Virus Neuraminidase Structure and Functions. McAuley JL, Gilbertson BP, Trifkovic S, Brown LE, McKimm-Breschkin JL. Front Microbiol 10 39 (2019)
  4. NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines? Krammer F, Fouchier RAM, Eichelberger MC, Webby RJ, Shaw-Saliba K, Wan H, Wilson PC, Compans RW, Skountzou I, Monto AS. mBio 9 e02332-17 (2018)
  5. In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen. Wohlbold TJ, Krammer F. Viruses 6 2465-2494 (2014)
  6. Influenza neuraminidase: a druggable target for natural products. Grienke U, Schmidtke M, von Grafenstein S, Kirchmair J, Liedl KR, Rollinger JM. Nat Prod Rep 29 11-36 (2012)
  7. Adaptive cellular stress pathways as therapeutic targets of dietary phytochemicals: focus on the nervous system. Lee J, Jo DG, Park D, Chung HY, Mattson MP. Pharmacol Rev 66 815-868 (2014)
  8. Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines. Marcelin G, Sandbulte MR, Webby RJ. Rev Med Virol 22 267-279 (2012)
  9. Principles of virus structural organization. Prasad BV, Schmid MF. Adv Exp Med Biol 726 17-47 (2012)
  10. Influenza genome analysis using pyrosequencing method: current applications for a moving target. Deyde VM, Gubareva LV. Expert Rev Mol Diagn 9 493-509 (2009)
  11. Influenza Neuraminidase Inhibitors: Synthetic Approaches, Derivatives and Biological Activity. Laborda P, Wang SY, Voglmeir J. Molecules 21 E1513 (2016)
  12. Influenza virus neuraminidase (NA): a target for antivirals and vaccines. Jagadesh A, Salam AA, Mudgal PP, Arunkumar G. Arch Virol 161 2087-2094 (2016)
  13. Influenza Neuraminidase Characteristics and Potential as a Vaccine Target. Creytens S, Pascha MN, Ballegeer M, Saelens X, de Haan CAM. Front Immunol 12 786617 (2021)
  14. Engineered Nanoparticle Applications for Recombinant Influenza Vaccines. Sia ZR, Miller MS, Lovell JF. Mol Pharm 18 576-592 (2021)
  15. Biosensor-based epitope mapping of antibodies targeting the hemagglutinin and neuraminidase of influenza A virus. Guo Z, Wilson JR, York IA, Stevens J. J Immunol Methods 461 23-29 (2018)
  16. A Tale of Three Recent Pandemics: Influenza, HIV and SARS-CoV-2. Miranda MNS, Pingarilho M, Pimentel V, Torneri A, Seabra SG, Libin PJK, Abecasis AB. Front Microbiol 13 889643 (2022)
  17. Conformation and Linkage Studies of Specific Oligosaccharides Related to H1N1, H5N1, and Human Flu for Developing the Second Tamiflu. Yoo E. Biomol Ther (Seoul) 22 93-99 (2014)
  18. Immune response in influenza virus infection and modulation of immune injury by viral neuraminidase. Jiang H, Zhang Z. Virol J 20 193 (2023)
  19. [Function of influenza virus RNA polymerase based on structure]. Naito T, Kawaguchi A, Nagata K. Uirusu 59 1-11 (2009)

Articles citing this publication (131)

  1. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. Wohlbold TJ, Nachbagauer R, Xu H, Tan GS, Hirsh A, Brokstad KA, Cox RJ, Palese P, Krammer F. mBio 6 e02556 (2015)
  2. Functional balance of the hemagglutinin and neuraminidase activities accompanies the emergence of the 2009 H1N1 influenza pandemic. Xu R, Zhu X, McBride R, Nycholat CM, Yu W, Paulson JC, Wilson IA. J Virol 86 9221-9232 (2012)
  3. Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. Margine I, Palese P, Krammer F. J Vis Exp e51112 (2013)
  4. The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. Li Q, Qi J, Zhang W, Vavricka CJ, Shi Y, Wei J, Feng E, Shen J, Chen J, Liu D, He J, Yan J, Liu H, Jiang H, Teng M, Li X, Gao GF. Nat Struct Mol Biol 17 1266-1268 (2010)
  5. Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses. Wan H, Gao J, Xu K, Chen H, Couzens LK, Rivers KH, Easterbrook JD, Yang K, Zhong L, Rajabi M, Ye J, Sultana I, Wan XF, Liu X, Perez DR, Taubenberger JK, Eichelberger MC. J Virol 87 9290-9300 (2013)
  6. Broadly protective human antibodies that target the active site of influenza virus neuraminidase. Stadlbauer D, Zhu X, McMahon M, Turner JS, Wohlbold TJ, Schmitz AJ, Strohmeier S, Yu W, Nachbagauer R, Mudd PA, Wilson IA, Ellebedy AH, Krammer F. Science 366 499-504 (2019)
  7. Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins. Nachbagauer R, Choi A, Hirsh A, Margine I, Iida S, Barrera A, Ferres M, Albrecht RA, García-Sastre A, Bouvier NM, Ito K, Medina RA, Palese P, Krammer F. Nat Immunol 18 464-473 (2017)
  8. NNScore: a neural-network-based scoring function for the characterization of protein-ligand complexes. Durrant JD, McCammon JA. J Chem Inf Model 50 1865-1871 (2010)
  9. Influenza virus neuraminidases with reduced enzymatic activity that avidly bind sialic Acid receptors. Zhu X, McBride R, Nycholat CM, Yu W, Paulson JC, Wilson IA. J Virol 86 13371-13383 (2012)
  10. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition. Vavricka CJ, Li Q, Wu Y, Qi J, Wang M, Liu Y, Gao F, Liu J, Feng E, He J, Wang J, Liu H, Jiang H, Gao GF. PLoS Pathog 7 e1002249 (2011)
  11. Structural and functional characterization of neuraminidase-like molecule N10 derived from bat influenza A virus. Li Q, Sun X, Li Z, Liu Y, Vavricka CJ, Qi J, Gao GF. Proc Natl Acad Sci U S A 109 18897-18902 (2012)
  12. Characterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza viruses. Wu Y, Bi Y, Vavricka CJ, Sun X, Zhang Y, Gao F, Zhao M, Xiao H, Qin C, He J, Liu W, Yan J, Qi J, Gao GF. Cell Res 23 1347-1355 (2013)
  13. Structures of phlebovirus glycoprotein Gn and identification of a neutralizing antibody epitope. Wu Y, Zhu Y, Gao F, Jiao Y, Oladejo BO, Chai Y, Bi Y, Lu S, Dong M, Zhang C, Huang G, Wong G, Li N, Zhang Y, Li Y, Feng WH, Shi Y, Liang M, Zhang R, Qi J, Gao GF. Proc Natl Acad Sci U S A 114 E7564-E7573 (2017)
  14. Analysis of the genetic diversity of influenza A viruses using next-generation DNA sequencing. Van den Hoecke S, Verhelst J, Vuylsteke M, Saelens X. BMC Genomics 16 79 (2015)
  15. The herpes simplex virus 1-encoded envelope glycoprotein B activates NF-κB through the Toll-like receptor 2 and MyD88/TRAF6-dependent signaling pathway. Cai M, Li M, Wang K, Wang S, Lu Q, Yan J, Mossman KL, Lin R, Zheng C. PLoS One 8 e54586 (2013)
  16. Structural characterization of a protective epitope spanning A(H1N1)pdm09 influenza virus neuraminidase monomers. Wan H, Yang H, Shore DA, Garten RJ, Couzens L, Gao J, Jiang L, Carney PJ, Villanueva J, Stevens J, Eichelberger MC. Nat Commun 6 6114 (2015)
  17. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus. Wang SQ, Du QS, Huang RB, Zhang DW, Chou KC. Biochem Biophys Res Commun 386 432-436 (2009)
  18. A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus. Marcelin G, DuBois R, Rubrum A, Russell CJ, McElhaney JE, Webby RJ. PLoS One 6 e26335 (2011)
  19. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses. Liu WC, Lin CY, Tsou YT, Jan JT, Wu SC. J Virol 89 7224-7234 (2015)
  20. Influenza A virus N5 neuraminidase has an extended 150-cavity. Wang M, Qi J, Liu Y, Vavricka CJ, Wu Y, Li Q, Gao GF. J Virol 85 8431-8435 (2011)
  21. Role of Neuraminidase in Influenza A(H7N9) Virus Receptor Binding. Benton DJ, Wharton SA, Martin SR, McCauley JW. J Virol 91 e02293-16 (2017)
  22. Induced opening of influenza virus neuraminidase N2 150-loop suggests an important role in inhibitor binding. Wu Y, Qin G, Gao F, Liu Y, Vavricka CJ, Qi J, Jiang H, Yu K, Gao GF. Sci Rep 3 1551 (2013)
  23. Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors. Vavricka CJ, Liu Y, Kiyota H, Sriwilaijaroen N, Qi J, Tanaka K, Wu Y, Li Q, Li Y, Yan J, Suzuki Y, Gao GF. Nat Commun 4 1491 (2013)
  24. Molecular Characterizations of Surface Proteins Hemagglutinin and Neuraminidase from Recent H5Nx Avian Influenza Viruses. Yang H, Carney PJ, Mishin VP, Guo Z, Chang JC, Wentworth DE, Gubareva LV, Stevens J. J Virol 90 5770-5784 (2016)
  25. Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies. Zhu X, Turner HL, Lang S, McBride R, Bangaru S, Gilchuk IM, Yu W, Paulson JC, Crowe JE, Ward AB, Wilson IA. Cell Host Microbe 26 729-738.e4 (2019)
  26. Detection of molecular markers of antiviral resistance in influenza A (H5N1) viruses using a pyrosequencing method. Deyde VM, Nguyen T, Bright RA, Balish A, Shu B, Lindstrom S, Klimov AI, Gubareva LV. Antimicrob Agents Chemother 53 1039-1047 (2009)
  27. Identifying selective inhibitors against the human cytosolic sialidase NEU2 by substrate specificity studies. Li Y, Cao H, Yu H, Chen Y, Lau K, Qu J, Thon V, Sugiarto G, Chen X. Mol Biosyst 7 1060-1072 (2011)
  28. A generic system for the expression and purification of soluble and stable influenza neuraminidase. Schmidt PM, Attwood RM, Mohr PG, Barrett SA, McKimm-Breschkin JL. PLoS One 6 e16284 (2011)
  29. An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo. Wilson JR, Guo Z, Reber A, Kamal RP, Music N, Gansebom S, Bai Y, Levine M, Carney P, Tzeng WP, Stevens J, York IA. Antiviral Res 135 48-55 (2016)
  30. Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective. Madsen A, Dai YN, McMahon M, Schmitz AJ, Turner JS, Tan J, Lei T, Alsoussi WB, Strohmeier S, Amor M, Mohammed BM, Mudd PA, Simon V, Cox RJ, Fremont DH, Krammer F, Ellebedy AH. Immunity 53 852-863.e7 (2020)
  31. Promising Anti-influenza Properties of Active Constituent of Withania somnifera Ayurvedic Herb in Targeting Neuraminidase of H1N1 Influenza: Computational Study. Cai Z, Zhang G, Tang B, Liu Y, Fu X, Zhang X. Cell Biochem Biophys 72 727-739 (2015)
  32. Active 1918 pandemic flu viral neuraminidase has distinct N-glycan profile and is resistant to trypsin digestion. Wu ZL, Ethen C, Hickey GE, Jiang W. Biochem Biophys Res Commun 379 749-753 (2009)
  33. Surface modifications of influenza proteins upon virus inactivation by β-propiolactone. She YM, Cheng K, Farnsworth A, Li X, Cyr TD. Proteomics 13 3537-3547 (2013)
  34. Impact of calcium on N1 influenza neuraminidase dynamics and binding free energy. Lawrenz M, Wereszczynski J, Amaro R, Walker R, Roitberg A, McCammon JA. Proteins 78 2523-2532 (2010)
  35. Microsecond Molecular Dynamics Simulations of Influenza Neuraminidase Suggest a Mechanism for the Increased Virulence of Stalk-Deletion Mutants. Durrant JD, Bush RM, Amaro RE. J Phys Chem B 120 8590-8599 (2016)
  36. Inhibitory potency of flavonoid derivatives on influenza virus neuraminidase. Rakers C, Schwerdtfeger SM, Mortier J, Duwe S, Wolff T, Wolber G, Melzig MF. Bioorg Med Chem Lett 24 4312-4317 (2014)
  37. Broadly Inhibiting Antineuraminidase Monoclonal Antibodies Induced by Trivalent Influenza Vaccine and H7N9 Infection in Humans. Rijal P, Wang BB, Tan TK, Schimanski L, Janesch P, Dong T, McCauley JW, Daniels RS, Townsend AR, Huang KA. J Virol 94 e01182-19 (2020)
  38. Identification of Residues That Affect Oligomerization and/or Enzymatic Activity of Influenza Virus H5N1 Neuraminidase Proteins. Dai M, Guo H, Dortmans JC, Dekkers J, Nordholm J, Daniels R, van Kuppeveld FJ, de Vries E, de Haan CA. J Virol 90 9457-9470 (2016)
  39. A Balance between Inhibitor Binding and Substrate Processing Confers Influenza Drug Resistance. Jiang L, Liu P, Bank C, Renzette N, Prachanronarong K, Yilmaz LS, Caffrey DR, Zeldovich KB, Schiffer CA, Kowalik TF, Jensen JD, Finberg RW, Wang JP, Bolon DNA. J Mol Biol 428 538-553 (2016)
  40. Functional and structural analysis of influenza virus neuraminidase N3 offers further insight into the mechanisms of oseltamivir resistance. Li Q, Qi J, Wu Y, Kiyota H, Tanaka K, Suhara Y, Ohrui H, Suzuki Y, Vavricka CJ, Gao GF. J Virol 87 10016-10024 (2013)
  41. Mutations in NA that induced low pH-stability and enhanced the replication of pandemic (H1N1) 2009 influenza A virus at an early stage of the pandemic. Takahashi T, Song J, Suzuki T, Kawaoka Y. PLoS One 8 e64439 (2013)
  42. Drug Susceptibility Evaluation of an Influenza A(H7N9) Virus by Analyzing Recombinant Neuraminidase Proteins. Gubareva LV, Sleeman K, Guo Z, Yang H, Hodges E, Davis CT, Baranovich T, Stevens J. J Infect Dis 216 S566-S574 (2017)
  43. Potential New H1N1 Neuraminidase Inhibitors from Ferulic Acid and Vanillin: Molecular Modelling, Synthesis and in Vitro Assay. Hariono M, Abdullah N, Damodaran KV, Kamarulzaman EE, Mohamed N, Hassan SS, Shamsuddin S, Wahab HA. Sci Rep 6 38692 (2016)
  44. Antiviral susceptibility of variant influenza A(H3N2)v viruses isolated in the United States from 2011 to 2013. Sleeman K, Mishin VP, Guo Z, Garten RJ, Balish A, Fry AM, Villanueva J, Stevens J, Gubareva LV. Antimicrob Agents Chemother 58 2045-2051 (2014)
  45. Enzymatic synthesis and properties of glycoconjugates with legionaminic acid as a replacement for neuraminic acid. Watson DC, Leclerc S, Wakarchuk WW, Young NM. Glycobiology 21 99-108 (2011)
  46. Neuraminidase inhibition of Dietary chlorogenic acids and derivatives - potential antivirals from dietary sources. Gamaleldin Elsadig Karar M, Matei MF, Jaiswal R, Illenberger S, Kuhnert N. Food Funct 7 2052-2059 (2016)
  47. Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase. McKimm-Breschkin JL, Williams J, Barrett S, Jachno K, McDonald M, Mohr PG, Saito T, Tashiro M. J Antimicrob Chemother 68 2210-2221 (2013)
  48. Evolutionary history and phylodynamics of influenza A and B neuraminidase (NA) genes inferred from large-scale sequence analyses. Xu J, Davis CT, Christman MC, Rivailler P, Zhong H, Donis RO, Lu G. PLoS One 7 e38665 (2012)
  49. Molecular docking of potential inhibitors for influenza H7N9. Liu Z, Zhao J, Li W, Wang X, Xu J, Xie J, Tao K, Shen L, Zhang R. Comput Math Methods Med 2015 480764 (2015)
  50. Structural restrictions for influenza neuraminidase activity promote adaptation and diversification. Wang H, Dou D, Östbye H, Revol R, Daniels R. Nat Microbiol 4 2565-2577 (2019)
  51. Combining molecular docking and molecular dynamics to predict the binding modes of flavonoid derivatives with the neuraminidase of the 2009 H1N1 influenza A virus. Lu SJ, Chong FC. Int J Mol Sci 13 4496-4507 (2012)
  52. Topological N-glycosylation and site-specific N-glycan sulfation of influenza proteins in the highly expressed H1N1 candidate vaccines. She YM, Farnsworth A, Li X, Cyr TD. Sci Rep 7 10232 (2017)
  53. Characterization of neuraminidases from the highly pathogenic avian H5N1 and 2009 pandemic H1N1 influenza A viruses. Wu J, Zhang F, Wang M, Xu C, Song J, Zhou J, Lin X, Zhang Y, Wu X, Tan W, Lu J, Zhao H, Gao J, Zhao P, Lu J, Wang Y. PLoS One 5 e15825 (2010)
  54. Identification of immunogenic consensus T-cell epitopes in globally distributed influenza-A H1N1 neuraminidase. Gupta SK, Srivastava M, Akhoon BA, Smita S, Schmitz U, Wolkenhauer O, Vera J, Gupta SK. Infect Genet Evol 11 308-319 (2011)
  55. Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor. Wu Y, Gao F, Qi J, Bi Y, Fu L, Mohan S, Chen Y, Li X, Pinto BM, Vavricka CJ, Tien P, Gao GF. J Virol 90 10693-10700 (2016)
  56. Synthesis of selective inhibitors against V. cholerae sialidase and human cytosolic sialidase NEU2. Khedri Z, Li Y, Cao H, Qu J, Yu H, Muthana MM, Chen X. Org Biomol Chem 10 6112-6120 (2012)
  57. CrystalDock: a novel approach to fragment-based drug design. Durrant JD, Friedman AJ, McCammon JA. J Chem Inf Model 51 2573-2580 (2011)
  58. Molecular characterization and comparative analysis of pandemic H1N1/2009 strains with co-circulating seasonal H1N1/2009 strains from eastern India. Sarkar M, Agrawal AS, Sharma Dey R, Chattopadhyay S, Mullick R, De P, Chakrabarti S, Chawla-Sarkar M. Arch Virol 156 207-217 (2011)
  59. NA proteins of influenza A viruses H1N1/2009, H5N1, and H9N2 show differential effects on infection initiation, virus release, and cell-cell fusion. Chen Q, Huang S, Chen J, Zhang S, Chen Z. PLoS One 8 e54334 (2013)
  60. The Postfusion Structure of the Heartland Virus Gc Glycoprotein Supports Taxonomic Separation of the Bunyaviral Families Phenuiviridae and Hantaviridae. Zhu Y, Wu Y, Chai Y, Qi J, Peng R, Feng WH, Gao GF. J Virol 92 e01558-17 (2018)
  61. Evaluation of the antigenic relatedness and cross-protective immunity of the neuraminidase between human influenza A (H1N1) virus and highly pathogenic avian influenza A (H5N1) virus. Lu X, Liu F, Zeng H, Sheu T, Achenbach JE, Veguilla V, Gubareva LV, Garten R, Smith C, Yang H, Stevens J, Xu X, Katz JM, Tumpey TM. Virology 454-455 169-175 (2014)
  62. Exploring the mechanism of zanamivir resistance in a neuraminidase mutant: a molecular dynamics study. Han N, Liu X, Mu Y. PLoS One 7 e44057 (2012)
  63. Influenza Virus Segment Composition Influences Viral Stability in the Environment. Labadie T, Batéjat C, Manuguerra JC, Leclercq I. Front Microbiol 9 1496 (2018)
  64. Potential drug-like inhibitors of Group 1 influenza neuraminidase identified through computer-aided drug design. Durrant JD, McCammon JA. Comput Biol Chem 34 97-105 (2010)
  65. A Novel Recombinant Influenza Virus Neuraminidase Vaccine Candidate Stabilized by a Measles Virus Phosphoprotein Tetramerization Domain Provides Robust Protection from Virus Challenge in the Mouse Model. Strohmeier S, Amanat F, Zhu X, McMahon M, Deming ME, Pasetti MF, Neuzil KM, Wilson IA, Krammer F. mBio 12 e0224121 (2021)
  66. Survival analysis of infected mice reveals pathogenic variations in the genome of avian H1N1 viruses. Koçer ZA, Fan Y, Huether R, Obenauer J, Webby RJ, Zhang J, Webster RG, Wu G. Sci Rep 4 7455 (2014)
  67. Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret Model. Liu WC, Nachbagauer R, Stadlbauer D, Strohmeier S, Solórzano A, Berlanda-Scorza F, Innis BL, García-Sastre A, Palese P, Krammer F, Albrecht RA. Vaccines (Basel) 9 40 (2021)
  68. Identification of novel compounds against an R294K substitution of influenza A (H7N9) virus using ensemble based drug virtual screening. Tran N, Van T, Nguyen H, Le L. Int J Med Sci 12 163-176 (2015)
  69. Parallel screening of wild-type and drug-resistant targets for anti-resistance neuraminidase inhibitors. Hsu KC, Hung HC, Horng JT, Fang MY, Chang CY, Li LT, Chen IJ, Chen YC, Chou DL, Chang CW, Hsieh HP, Yang JM, Hsu JT. PLoS One 8 e56704 (2013)
  70. Structural and functional analysis of surface proteins from an A(H3N8) influenza virus isolated from New England harbor seals. Yang H, Nguyen HT, Carney PJ, Guo Z, Chang JC, Jones J, Davis CT, Villanueva JM, Gubareva LV, Stevens J. J Virol 89 2801-2812 (2015)
  71. Young adolescents who combine alcohol and energy drinks have a higher risk of reporting negative behavioural outcomes. Holubcikova J, Kolarcik P, Madarasova Geckova A, Joppova E, van Dijk JP, Reijneveld SA. Int J Public Health 62 379-386 (2017)
  72. Analysis of the Evolution of Pandemic Influenza A(H1N1) Virus Neuraminidase Reveals Entanglement of Different Phenotypic Characteristics. Dai M, Du W, Martínez-Romero C, Leenders T, Wennekes T, Rimmelzwaan GF, van Kuppeveld FJM, Fouchier RAM, Garcia-Sastre A, de Vries E, de Haan CAM. mBio 12 e00287-21 (2021)
  73. Evidence of ternary complex formation in Trypanosoma cruzi trans-sialidase catalysis. Oliveira IA, Gonçalves AS, Neves JL, von Itzstein M, Todeschini AR. J Biol Chem 289 423-436 (2014)
  74. Structure-based design of stabilized recombinant influenza neuraminidase tetramers. Ellis D, Lederhofer J, Acton OJ, Tsybovsky Y, Kephart S, Yap C, Gillespie RA, Creanga A, Olshefsky A, Stephens T, Pettie D, Murphy M, Sydeman C, Ahlrichs M, Chan S, Borst AJ, Park YJ, Lee KK, Graham BS, Veesler D, King NP, Kanekiyo M. Nat Commun 13 1825 (2022)
  75. Letter 2-Pyridinyl-4(3H)-quinazolinone: a scaffold for anti-influenza A virus compounds. Liu S, Wang W, Jiang L, Wan S, Zhang L, Yu R, Jiang T. Chem Biol Drug Des 86 1221-1225 (2015)
  76. Deep sequencing of 2009 influenza A/H1N1 virus isolated from volunteer human challenge study participants and natural infections. Xiao Y, Park JK, Williams S, Ramuta M, Cervantes-Medina A, Bristol T, Smith S, Czajkowski L, Han A, Kash JC, Memoli MJ, Taubenberger JK. Virology 534 96-107 (2019)
  77. Design of the Recombinant Influenza Neuraminidase Antigen Is Crucial for Its Biochemical Properties and Protective Efficacy. Gao J, Klenow L, Parsons L, Malik T, Phue JN, Gao Z, Withers SG, Cipollo J, Daniels R, Wan H. J Virol 95 e0116021 (2021)
  78. Gallus gallus NEU3 sialidase as model to study protein evolution mechanism based on rapid evolving loops. Giacopuzzi E, Barlati S, Preti A, Venerando B, Monti E, Borsani G, Bresciani R. BMC Biochem 12 45 (2011)
  79. Introduction of Cysteines in the Stalk Domain of Recombinant Influenza Virus N1 Neuraminidase Enhances Protein Stability and Immunogenicity in Mice. Strohmeier S, Carreño JM, Brito RN, Krammer F. Vaccines (Basel) 9 404 (2021)
  80. The nonadaptive nature of the H1N1 2009 Swine Flu pandemic contrasts with the adaptive facilitation of transmission to a new host. Abdussamad J, Aris-Brosou S. BMC Evol Biol 11 6 (2011)
  81. A Novel Natural Influenza A H1N1 Virus Neuraminidase Inhibitory Peptide Derived from Cod Skin Hydrolysates and Its Antiviral Mechanism. Li J, Chen Y, Yuan N, Zeng M, Zhao Y, Yu R, Liu Z, Wu H, Dong S. Mar Drugs 16 E377 (2018)
  82. Drivers of recombinant soluble influenza A virus hemagglutinin and neuraminidase expression in mammalian cells. van der Woude R, Turner HL, Tomris I, Bouwman KM, Ward AB, de Vries RP. Protein Sci 29 1975-1982 (2020)
  83. Flavonol dimers from callus cultures of Dysosma versipellis and their in vitro neuraminidase inhibitory activities. Chen R, Duan R, Wei Y, Zou J, Li J, Liu X, Wang H, Guo Y, Li Q, Dai J. Fitoterapia 107 77-84 (2015)
  84. Molecular Docking Studies and Biological Evaluation of Berberine-Benzothiazole Derivatives as an Anti-Influenza Agent via Blocking of Neuraminidase. Kumar M, Chung SM, Enkhtaivan G, Patel RV, Shin HS, Mistry BM. Int J Mol Sci 22 2368 (2021)
  85. Anti-Neuraminidase Bioactives from Manggis Hutan (Garcinia celebica L.) Leaves: Partial Purification and Molecular Characterization. Muchtaridi M, Sugijanto M, Mohd Gazzali A, Wahab HA. Molecules 25 E821 (2020)
  86. Design of multiligand inhibitors for the swine flu H1N1 neuraminidase binding site. Narayanan MM, Nair CB, Sanjeeva SK, Rao PS, Pullela PK, Barrow CJ. Adv Appl Bioinform Chem 6 47-53 (2013)
  87. Five Novel Non-Sialic Acid-Like Scaffolds Inhibit In Vitro H1N1 and H5N2 Neuraminidase Activity of Influenza a Virus. Márquez-Domínguez L, Reyes-Leyva J, Herrera-Camacho I, Santos-López G, Scior T. Molecules 25 E4248 (2020)
  88. Molecular modeling of swine influenza A/H1N1, Spanish H1N1, and avian H5N1 flu N1 neuraminidases bound to Tamiflu and Relenza. Le L, Lee E, Schulten K, Truong TN. PLoS Curr 1 RRN1015 (2009)
  89. Phylogenetic analysis of surface proteins of novel H1N1 virus isolated from 2009 pandemic. Danishuddin M, Khan SN, Khan AU. Bioinformation 4 94-97 (2009)
  90. Receptor recognition mechanism of human influenza A H1N1 (1918), avian influenza A H5N1 (2004), and pandemic H1N1 (2009) neuraminidase. Jongkon N, Sangma C. J Mol Model 18 285-293 (2012)
  91. Tracking the evolution and geographic spread of Influenza A. Donovan Parks, Macdonald N, Beiko R. PLoS Curr 1 RRN1014 (2009)
  92. A Screening of Neuraminidase Inhibition Activities of Isoquinolone Alkaloids in Coptis chinensis Using Molecular Docking and Pharmacophore Analysis. Le K, Tran D, Nguyen A, Le L. ACS Omega 5 30315-30322 (2020)
  93. A negative stain for electron microscopic tomography. Fera A, Farrington JE, Zimmerberg J, Reese TS. Microsc Microanal 18 331-335 (2012)
  94. Computational modeling and validation studies of 3-D structure of neuraminidase protein of H1N1 influenza A virus and subsequent in silico elucidation of piceid analogues as its potent inhibitors. Gupta CL, Akhtar S, Bajpaib P, Kandpal KN, Desai GS, Tiwari AK. EXCLI J 12 215-225 (2013)
  95. Core-6 fucose and the oligomerization of the 1918 pandemic influenza viral neuraminidase. Wu ZL, Zhou H, Ethen CM, N Reinhold V. Biochem Biophys Res Commun 473 524-529 (2016)
  96. Evaluation of a Set of C9 N-acyl Neu5Ac2en Mimetics as Viral Sialidase Selective Inhibitors. Magesh S, Sriwilaijaroen N, Moriya S, Ando H, Miyagi T, Suzuki Y, Ishida H, Kiso M. Int J Med Chem 2011 539245 (2011)
  97. Influenza chimeric hemagglutinin structures in complex with broadly protective antibodies to the stem and trimer interface. Zhu X, Han J, Sun W, Puente-Massaguer E, Yu W, Palese P, Krammer F, Ward AB, Wilson IA. Proc Natl Acad Sci U S A 119 e2200821119 (2022)
  98. Progress in structure-based drug design against influenza A virus. Du QS, Wei H, Huang RB, Chou KC. Expert Opin Drug Discov 6 619-631 (2011)
  99. Structure Optimization of Neuraminidase Inhibitors as Potential Anti-Influenza (H1N1Inhibitors) Agents Using QSAR and Molecular Docking Studies. Inamdar P, Bhandari S, Sonawane B, Hole A, Jadhav C. Iran J Pharm Res 13 49-65 (2014)
  100. Variability of tropism and replicative capacity of two naturally occurring influenza A H9N2 viruses in cell cultures from different tissues. Tombari W, ElBehi I, Amouna F, Ghram A. Avian Pathol 45 212-220 (2016)
  101. Antiviral compound screening, peptide designing, and protein network construction of influenza a virus (strain a/Puerto Rico/8/1934 H1N1). Saikia S, Bordoloi M, Sarmah R, Kolita B. Drug Dev Res 80 106-124 (2019)
  102. Genetic analysis of neuraminidase gene of influenza A(H1N1)pdm09 virus circulating in Southwest India from 2009 to 2012. Jagadesh A, Salam AA, Zadeh VR, Arunkumar G. J Med Virol 89 202-212 (2017)
  103. Molecular dynamics directed CoMFA studies on carbocyclic neuraminidase inhibitors. Chavan S, Bhayye S, Sobhia ME. Mol Divers 15 979-987 (2011)
  104. Monoclonal antibody against N2 neuraminidase of cold adapted A/Leningrad/134/17/57 (H2N2) enables efficient generation of live attenuated influenza vaccines. Shcherbik S, Carney P, Pearce N, Stevens J, Dugan VG, Wentworth DE, Bousse T. Virology 522 65-72 (2018)
  105. Platform for determining the inhibition profile of neuraminidase inhibitors in an influenza virus N1 background. Hoffmann A, Schade D, Kirchmair J, Clement B, Sauerbrei A, Schmidtke M. J Virol Methods 237 192-199 (2016)
  106. SeqMonitor: influenza analysis pipeline and visualization. Macdonald N, Parks D, Beiko R. PLoS Curr 1 RRN1040 (2009)
  107. Structural basis for the inhibition of 1,3-1,4-β-D-glucanase by noncompetitive calcium ion and competitive Tris inhibitors. Tsai LC, Hsiao CH, Liu WY, Yin LM, Shyur LF. Biochem Biophys Res Commun 407 593-598 (2011)
  108. Structure-based design of 5'-substituted 1,2,3-triazolylated oseltamivir derivatives as potent influenza neuraminidase inhibitors. Wang P, Oladejo BO, Li C, Fu L, Zhang S, Qi J, Lv X, Li X. RSC Adv 11 9528-9541 (2021)
  109. The Mechanism by which 146-N-Glycan Affects the Active Site of Neuraminidase. Liu P, Wang Z, Zhang L, Li D, Lin J. PLoS One 10 e0135487 (2015)
  110. Antibodies targeting the neuraminidase active site inhibit influenza H3N2 viruses with an S245N glycosylation site. Stadlbauer D, McMahon M, Turner HL, Zhu X, Wan H, Carreño JM, O'Dell G, Strohmeier S, Khalil Z, Luksza M, van Bakel H, Simon V, Ellebedy AH, Wilson IA, Ward AB, Krammer F. Nat Commun 13 7864 (2022)
  111. Bayesian coalescent analysis of pandemic H1N1 influenza A virus circulating in the South American region. Goñi N, Moratorio G, Coppola L, Ramas V, Comas V, Soñora M, Chiparelli H, Cristina J. Virus Res 170 91-101 (2012)
  112. Bifunctional Inhibitors of Influenza Virus Neuraminidase: Molecular Design of a Sulfonamide Linker. Evteev S, Nilov D, Polenova A, Švedas V. Int J Mol Sci 22 13112 (2021)
  113. Comparative thermostability analysis of zoonotic and human influenza virus A and B neuraminidase. Evseenko VA, Svyatchenko SV, Kolosova NP, Kovrizhkina VL, Marchenko VY, Durymanov AG, Goncharova NI, Ryzhikov AB. Arch Virol 165 201-206 (2020)
  114. Development of a surface plasmon resonance assay to measure the binding affinity of wild-type influenza neuraminidase and its H274Y mutant to the antiviral drug zanamivir. Somasundaram B, Fee CJ, Fredericks R, Watson AJ, Fairbanks AJ. J Mol Recognit 28 87-95 (2015)
  115. Molecular characterization of neuraminidase genes of influenza A(H3N2) viruses circulating in Southwest India from 2009 to 2013. Jagadesh A, Salam AAA, Zadeh VR, Krishnan A, Arunkumar G. Arch Virol 162 1887-1902 (2017)
  116. Neuraminidase Inhibitor of Garcinia atroviridis L. Fruits and Leaves Using Partial Purification and Molecular Characterization. Muchtaridi M, Nuwarda RF, Ikram EHK, Abdul Rahim AS, Gazzali AM, Wahab HA. Molecules 27 949 (2022)
  117. Structure prediction and analysis of neuraminidase sequence variants. Thayer KM. Biochem Mol Biol Educ 44 361-376 (2016)
  118. Substrate specificity of avian influenza H5N1 neuraminidase. Onsirisakul N, Nakakita S, Boonarkart C, Kongchanagul A, Suptawiwat O, Puthavathana P, Chaichuen K, Kittiniyom K, Suzuki Y, Auewarakul P. World J Virol 3 30-36 (2014)
  119. Triplet entropy analysis of hemagglutinin and neuraminidase sequences measures influenza virus phylodynamics. Gerhardt GJ, Takeda AA, Andrighetti T, Sartor IT, Echeverrigaray SL, de Avila E Silva S, Dos Santos L, Rybarczyk-Filho JL. Gene 528 277-281 (2013)
  120. Computational analysis and modeling the effectiveness of 'Zanamivir' targeting neuraminidase protein in pandemic H1N1 strains. Gupta SK, Gupta SK, Smita S, Srivastava M, Lai X, Schmitz U, Rahman Q, Wolkenhauer O, Vera J. Infect Genet Evol 11 1072-1082 (2011)
  121. Human anti-N1 monoclonal antibodies elicited by pandemic H1N1 virus infection broadly inhibit HxN1 viruses in vitro and in vivo. Hansen L, McMahon M, Turner HL, Zhu X, Turner JS, Ozorowski G, Stadlbauer D, Vahokoski J, Schmitz AJ, Rizk AA, Alsoussi WB, Strohmeier S, Yu W, Choreño-Parra JA, Jiménez-Alvarez L, Cruz-Lagunas A, Zúñiga J, Mudd PA, Cox RJ, Wilson IA, Ward AB, Ellebedy AH, Krammer F. Immunity 56 1927-1938.e8 (2023)
  122. Immunity induced by vaccination with recombinant influenza B virus neuraminidase protein breaks viral transmission chains in guinea pigs in an exposure intensity-dependent manner. McMahon M, Tan J, O'Dell G, Kirkpatrick Roubidoux E, Strohmeier S, Krammer F. J Virol e0105723 (2023)
  123. Impact of tetramerization on the ligand recognition of N1 influenza neuraminidase via MMGBSA approach. Bello M. Biopolymers 110 e23251 (2019)
  124. Leveraging vaccination-induced protective antibodies to define conserved epitopes on influenza N2 neuraminidase. Lei R, Kim W, Lv H, Mou Z, Scherm MJ, Schmitz AJ, Turner JS, Tan TJC, Wang Y, Ouyang WO, Liang W, Rivera-Cardona J, Teo C, Graham CS, Brooke CB, Presti RM, Mok CKP, Krammer F, Dai X, Ellebedy AH, Wu NC. Immunity 56 2621-2634.e6 (2023)
  125. Molecular modeling and phylogenetic analyses highlight the role of amino acid 347 of the N1 subtype neuraminidase in influenza virus host range and interspecies adaptation. Elli S, Raffaini G, Guerrini M, Kosakovsky Pond S, Matrosovich M. Front Microbiol 14 1309156 (2023)
  126. Nanobiological studies on drug design using molecular mechanic method. Ghaheh HS, Mousavi M, Araghi M, Rasoolzadeh R, Hosseini Z. Adv Biomed Res 4 219 (2015)
  127. Pre-existing Fc profiles shape the evolution of neutralizing antibody breadth following influenza vaccination. Boudreau CM, Burke JS, Roederer AL, Gorman MJ, Mundle S, Lingwood D, Delagrave S, Sridhar S, Ross TM, Kleanthous H, Alter G. Cell Rep Med 4 100975 (2023)
  128. Sequence Matching between Hemagglutinin and Neuraminidase through Sequence Analysis Using Machine Learning. Wang H, Zang Y, Zhao Y, Hao D, Kang Y, Zhang J, Zhang Z, Zhang L, Yang Z, Zhang S. Viruses 14 469 (2022)
  129. Structural and inhibitor sensitivity analysis of influenza B-like viral neuraminidases derived from Asiatic toad and spiny eel. Li L, Chai Y, Peng W, Li D, Sun L, Gao GF, Qi J, Xiao H, Liu WJ, von Itzstein M, Gao F. Proc Natl Acad Sci U S A 119 e2210724119 (2022)
  130. The arrival of highly pathogenic avian influenza viruses H5N8 in Iran through two windows, 2016. Motahhar M, Keyvanfar H, Shoushtari A, Fallah Mehrabadi MH, Nikbakht Brujeni G. Virus Genes 58 527-539 (2022)
  131. The hydrophobic side chain of oseltamivir influences type A subtype selectivity of neuraminidase inhibitors. Lin X, Qin-Hua C, Peng L, Chun-Lei L, Guang-De Y. Chem Biol Drug Des 91 105-115 (2018)


Quick links